Cargando…

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis

BACKGROUND: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in infancy with a complex pathology. In adults, the clinical severity of AD has been associated with increases in T helper cell type (Th) 2, Th22, and Th17 serum markers, including high levels of CC chemokine lig...

Descripción completa

Detalles Bibliográficos
Autores principales: Hulshof, Lies, Overbeek, Saskia A., Wyllie, Anne L., Chu, Mei Ling J. N., Bogaert, Debby, de Jager, Wilco, Knippels, Leon M. J., Sanders, Elisabeth A. M., van Aalderen, Wim M. C., Garssen, Johan, van’t Land, Belinda, Sprikkelman, Aline B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884950/
https://www.ncbi.nlm.nih.gov/pubmed/29966024
http://dx.doi.org/10.3389/fimmu.2018.00630
_version_ 1783311911485440000
author Hulshof, Lies
Overbeek, Saskia A.
Wyllie, Anne L.
Chu, Mei Ling J. N.
Bogaert, Debby
de Jager, Wilco
Knippels, Leon M. J.
Sanders, Elisabeth A. M.
van Aalderen, Wim M. C.
Garssen, Johan
van’t Land, Belinda
Sprikkelman, Aline B.
author_facet Hulshof, Lies
Overbeek, Saskia A.
Wyllie, Anne L.
Chu, Mei Ling J. N.
Bogaert, Debby
de Jager, Wilco
Knippels, Leon M. J.
Sanders, Elisabeth A. M.
van Aalderen, Wim M. C.
Garssen, Johan
van’t Land, Belinda
Sprikkelman, Aline B.
author_sort Hulshof, Lies
collection PubMed
description BACKGROUND: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in infancy with a complex pathology. In adults, the clinical severity of AD has been associated with increases in T helper cell type (Th) 2, Th22, and Th17 serum markers, including high levels of CC chemokine ligand (CCL) 17 and CCL22 chemokines. OBJECTIVE: To explore the possible association between serum chemokine levels and AD severity in infants with moderate-to-severe AD and elevated immunoglobulin E (IgE). SUBJECTS AND METHODS: Serum samples (n = 41) obtained from a randomized, double-blind, and clinical dietary intervention study were used to study biomarkers in infants with AD. Baseline- and post-intervention samples (4 months) were used, six chemokines and nine ratios thereof were analyzed using Luminex and correlated to AD severity. In the initial study, the infants were randomized to receive extensively hydrolyzed whey-based formula without (control) or with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active). RESULTS: 31 Infants up to 11 months of age, with an objective-SCORAD score (oSCORAD) ≥ 20 and elevated total-IgE and/or specific-IgE levels were included. In time, the median oSCORAD decreased in both groups by −8 (control, p < 0.05; active, p < 0.01). Irrespective of dietary intervention, several changes in Th2 chemokines (CCL17 and CCL22), inflammatory chemokine (CCL20), and the Th1 chemokine, CXC chemokine ligand (CXCL) 9, were detected over time. Overall CCL17 correlated to oSCORAD (r = 0.446, p < 0.01). After 4 months of dietary intervention, CXCL9 was higher (p < 0.01) in the active group compared with control [active, 2.33 (1.99–2.89); controls, 1.95 (1.77–2.43) log 10 median (range)]. In addition, a reduction in Th2/Th1 chemokine ratios for CCL17/CXCL9, CCL22/CXCL9, CCL20/CXCL10, and CCL20/CXCL11 was detected associated with the active intervention. CONCLUSION: While this study is small and exploratory in nature, these data contribute to immune biomarker profiling and understanding of AD in infants.
format Online
Article
Text
id pubmed-5884950
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58849502018-04-12 Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis Hulshof, Lies Overbeek, Saskia A. Wyllie, Anne L. Chu, Mei Ling J. N. Bogaert, Debby de Jager, Wilco Knippels, Leon M. J. Sanders, Elisabeth A. M. van Aalderen, Wim M. C. Garssen, Johan van’t Land, Belinda Sprikkelman, Aline B. Front Immunol Immunology BACKGROUND: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in infancy with a complex pathology. In adults, the clinical severity of AD has been associated with increases in T helper cell type (Th) 2, Th22, and Th17 serum markers, including high levels of CC chemokine ligand (CCL) 17 and CCL22 chemokines. OBJECTIVE: To explore the possible association between serum chemokine levels and AD severity in infants with moderate-to-severe AD and elevated immunoglobulin E (IgE). SUBJECTS AND METHODS: Serum samples (n = 41) obtained from a randomized, double-blind, and clinical dietary intervention study were used to study biomarkers in infants with AD. Baseline- and post-intervention samples (4 months) were used, six chemokines and nine ratios thereof were analyzed using Luminex and correlated to AD severity. In the initial study, the infants were randomized to receive extensively hydrolyzed whey-based formula without (control) or with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active). RESULTS: 31 Infants up to 11 months of age, with an objective-SCORAD score (oSCORAD) ≥ 20 and elevated total-IgE and/or specific-IgE levels were included. In time, the median oSCORAD decreased in both groups by −8 (control, p < 0.05; active, p < 0.01). Irrespective of dietary intervention, several changes in Th2 chemokines (CCL17 and CCL22), inflammatory chemokine (CCL20), and the Th1 chemokine, CXC chemokine ligand (CXCL) 9, were detected over time. Overall CCL17 correlated to oSCORAD (r = 0.446, p < 0.01). After 4 months of dietary intervention, CXCL9 was higher (p < 0.01) in the active group compared with control [active, 2.33 (1.99–2.89); controls, 1.95 (1.77–2.43) log 10 median (range)]. In addition, a reduction in Th2/Th1 chemokine ratios for CCL17/CXCL9, CCL22/CXCL9, CCL20/CXCL10, and CCL20/CXCL11 was detected associated with the active intervention. CONCLUSION: While this study is small and exploratory in nature, these data contribute to immune biomarker profiling and understanding of AD in infants. Frontiers Media S.A. 2018-03-29 /pmc/articles/PMC5884950/ /pubmed/29966024 http://dx.doi.org/10.3389/fimmu.2018.00630 Text en Copyright © 2018 Hulshof, Overbeek, Wyllie, Chu, Bogaert, de Jager, Knippels, Sanders, van Aalderen, Garssen, van’t Land, Sprikkelman and The Clinical Study Group. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hulshof, Lies
Overbeek, Saskia A.
Wyllie, Anne L.
Chu, Mei Ling J. N.
Bogaert, Debby
de Jager, Wilco
Knippels, Leon M. J.
Sanders, Elisabeth A. M.
van Aalderen, Wim M. C.
Garssen, Johan
van’t Land, Belinda
Sprikkelman, Aline B.
Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
title Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
title_full Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
title_fullStr Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
title_full_unstemmed Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
title_short Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
title_sort exploring immune development in infants with moderate to severe atopic dermatitis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884950/
https://www.ncbi.nlm.nih.gov/pubmed/29966024
http://dx.doi.org/10.3389/fimmu.2018.00630
work_keys_str_mv AT hulshoflies exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT overbeeksaskiaa exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT wyllieannel exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT chumeilingjn exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT bogaertdebby exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT dejagerwilco exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT knippelsleonmj exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT sanderselisabetham exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT vanaalderenwimmc exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT garssenjohan exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT vantlandbelinda exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT sprikkelmanalineb exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis
AT exploringimmunedevelopmentininfantswithmoderatetosevereatopicdermatitis